Eswatini vs Myanmar: HIV/AIDS deaths averted by antiretroviral therapy
Eswatini
10,530 deaths
in 2024
Myanmar
8,848 deaths
in 2024
Eswatini rank
24th
Myanmar rank
26th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Eswatini
- Myanmar
How they compare
Eswatini currently reports 10,530 deaths against 8,848 deaths in Myanmar, a difference of 1,682 deaths.
That makes Eswatini's figure about 1.2 times Myanmar's.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Myanmar ahead.
Eswatini ranks 24th and Myanmar ranks 26th of 157 countries.
Eswatini has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Eswatini | Myanmar | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 2,256 deaths | 792.59 deaths | 1,463 deaths | Eswatini |
| 2010s | 9,542 deaths | 7,079 deaths | 2,463 deaths | Eswatini |
| 2020s | 10,848 deaths | 9,387 deaths | 1,461 deaths | Eswatini |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Eswatini or Myanmar?
- Eswatini, at 10,530 deaths against 8,848 deaths in Myanmar as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Eswatini and Myanmar?
- 1,682 deaths, with Eswatini ahead.
- How many years of comparable data are there for Eswatini and Myanmar?
- 35 years are reported by both, from 1990 to 2024.
- How do Eswatini and Myanmar rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Eswatini ranks 24th and Myanmar ranks 26th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.